Technology
ETH Biotech spin-off based in Zurich
Driving innovation in gene therapy for treating genetic disorders
Evis Bioscience is pioneering a patented and versatile technology to produce hybrid extracellular vesicles for targeted and safe delivery of small and large ribonucleic acids
Hybrid EV-based platforms for RNAs and gene-editing tools delivery
Our proprietary technology combines natural extracellular vesicles and lipid-based nanovectors to achieve targeted, efficient, and safe RNA delivery for medical applications.
Service
We support research laboratories by providing access to our technology and expertise in gene delivery using extracellular vesicles
Our service includes:
Loading nucleic acids into your extracellular vesicles
We load your extracellular vesicles with small and large nucleic acids using advanced protocols while retaining the biological activity of the vesicles
Physico-chemical characterization of your formulation
We perform a comprehensive analysis of your formulation to ensure quality and consistency. You will receive a full report including results and recommendations
Independent application
We offer chemical kits that enable the loading of nucleic acids into your extracellular vesicles directly in your own lab
Sublicenses
We support pharmaceutical companies by licensing our proprietary hybrid technology to deliver therapeutic RNAs
Through our licensing program, you can access our platform to load RNAs into extracellular vesicles and develop extra-hepatic and targeted gene delivery-based therapies
Why partner with us:
JOIN THE INNOVATION
Interested in leveraging our services?
Connect with us to initiate a powerful collaboration.